Nieuws Regulated Transparency/Denominator Regulated Information / Transparency Statement EN NL april 27, 2018
General Nieuws ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME EN april 27, 2018
General Nieuws ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149 EN april 6, 2018
General Nieuws ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317 for the Treatment of Diabetic Macular Edema (DME) EN april 4, 2018
General Nieuws Regulated Disclosure in accordance with Belgian Law of 2 May 2007 EN NL januari 30, 2018
Nieuws Regulated Transparency/Denominator NOVARTIS PHARMA AG HOLDING 5.69% OF THROMBOGENICS EQUITY CAPITAL EN NL januari 26, 2018
